StonvexLoading…
StonvexCore line items from CHRD's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q3 2026 (Est.) Expected 2026-08-04 | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|---|
Revenue | $1.51B | $1.67B | $4.88B | $3.71B | $2.40B |
Operating Income | Not available | $333.22M | $197.43M | $105.57M | $-65.22M |
Net Income | Not available | $108.61M | $44.46M | $-39.96M | $-170.07M |
EPS (Diluted) | $5.57 | $1.90 | $0.74 | $-0.72 | $-2.93 |
Total Assets | Not available | $13.24B | $13.07B | $13.10B | $12.55B |
Total Liabilities | Not available | $5.19B | $4.99B | $5.02B | $4.45B |
Cash & Equivalents | Not available | $225.80M | $189.53M | $629.21M | $40.49M |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available | Not available |
Shares Outstanding | Not available | 56.28M | 56.76M | 56.87M | 57.65M |